Immunology vs Rare Disease — Deal Terms Comparison
Market Analysis
Immunology and Rare Disease represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 immunology deals carry a median total deal value of $2.5B with $480M upfront, compared to $1.6B total value and $285M upfront for rare disease. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do immunology and rare disease deal terms compare?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.